[ET Net News Agency, 6 January 2026] UBS lowered the target price for JD Health (06618)
to HKD78 from HKD85 and maintained the "buy" rating.
The research house said it expects revenue growth in Q425 to be stronger than the
company's previous guidance (low-teens %). (rc)